NFE2L2 and cancer: According to eleven pan-cancer sequencing studies on 101,679 samples from 100,611 patients, NRF2, KEAP1, and CUL3 mutation took place in 1.8%, 4%, and 1.3% cases, respectively (Figure 2B).